Clinical testing of children with suspected pediatric acute-onset neuropsychiatric syndrome does not help identify the ...

Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric ...

Axsome obtains exclusive global rights to balipodect, a potentially first-in-class selective phosphodiesterase 10A inhibitor ...

A $10.3 million grant from the California Institute for Regenerative Medicine (CIRM), the state’s stem cell agency, will fund a multi-UC effort to better understand neuropsychiatric disorders. One in ...

Gilgamesh Pharma, a clinical-stage neuroscience company developing breakthrough therapies for psychiatric and neurological disorders, today announced the successful closing of a $60 million Series A ...

Amani Therapeutics, a newly formed biotechnology company backed by RTW Investments, today announced the closing of a $25 million Series A financing. The company also announced the appointment of its ...

Aging is accompanied by increasing rates of cognitive disorders and neuropsychiatric symptoms (NPS) including depression, anxiety, apathy, agitation, sleep ...

A large cohort study showed no association between use of acid-suppressant medications in pregnancy and neuropsychiatric outcomes in offspring after controlling for familial factors. Initial analyses ...

In a genetic association study, investigators integrated data from genome-wide association studies of various disorders with retinal transcriptomic data. Findings revealed that the polygenic risk of ...

India's first open-source psychiatric disorders database, CALM-Brain, launched in Bengaluru, aims to enhance understanding ...

What do depression, Alzheimer's disease and autism have in common? Well, according to new research, they may all be underpinned by an increasing level of acidity in our brains. Scientists have long ...